These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 31318138)

  • 1. OLFM4 Expression in Ductal Carcinoma In Situ and in Invasive Breast Cancer Cohorts by a SWATH-Based Proteomic Approach.
    Valo I; Raro P; Boissard A; Maarouf A; Jézéquel P; Verriele V; Campone M; Coqueret O; Guette C
    Proteomics; 2019 Nov; 19(21-22):e1800446. PubMed ID: 31318138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
    Asch HL; Winston JS; Edge SB; Stomper PC; Asch BB
    Breast Cancer Res Treat; 1999 May; 55(2):179-88. PubMed ID: 10481945
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma.
    Duan C; Liu X; Liang S; Yang Z; Xia M; Wang L; Chen S; Yu L
    J Cell Mol Med; 2014 May; 18(5):863-74. PubMed ID: 24495253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A quantitative proteomic approach of the different stages of colorectal cancer establishes OLFM4 as a new nonmetastatic tumor marker.
    Besson D; Pavageau AH; Valo I; Bourreau A; Bélanger A; Eymerit-Morin C; Moulière A; Chassevent A; Boisdron-Celle M; Morel A; Solassol J; Campone M; Gamelin E; Barré B; Coqueret O; Guette C
    Mol Cell Proteomics; 2011 Dec; 10(12):M111.009712. PubMed ID: 21986994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.
    Li H; Kim C; Liu W; Zhu J; Chin K; Rodriguez-Canales J; Rodgers GP
    Int J Cancer; 2020 Mar; 146(5):1346-1358. PubMed ID: 31241767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
    Storm FK; Gilchrist KW; Warner TF; Mahvi DM
    Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic silencing of olfactomedin-4 enhances gastric cancer cell invasion via activation of focal adhesion kinase signaling.
    Guo LL; He ZC; Yang CQ; Qiao PT; Yin GL
    BMB Rep; 2015 Nov; 48(11):630-5. PubMed ID: 26303970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific overexpression of OLFM4(GW112/HGC-1) mRNA in colon, breast and lung cancer tissues detected using quantitative analysis.
    Koshida S; Kobayashi D; Moriai R; Tsuji N; Watanabe N
    Cancer Sci; 2007 Mar; 98(3):315-20. PubMed ID: 17270020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Olfactomedin-4 in digestive diseases: A mini-review.
    Wang XY; Chen SH; Zhang YN; Xu CF
    World J Gastroenterol; 2018 May; 24(17):1881-1887. PubMed ID: 29740203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Olfactomedin-related proteins 4 (OLFM4) expression is involved in early gastric carcinogenesis and of prognostic significance in advanced gastric cancer.
    Jang BG; Lee BL; Kim WH
    Virchows Arch; 2015 Sep; 467(3):285-94. PubMed ID: 26070873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low expression of olfactomedin 4 correlates with poor prognosis in smoking patients with non-small cell lung cancer.
    Su W; Luo L; Wu F; Lai Z; Li X; Xie Z; Tang Z; Yang Z; Liang R
    Hum Pathol; 2015 May; 46(5):732-8. PubMed ID: 25771901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olfactomedin 4 associates with expression of differentiation markers but not with properties of cancer stemness, EMT nor metastatic spread in colorectal cancer.
    Jaitner S; Pretzsch E; Neumann J; Schäffauer A; Schiemann M; Angele M; Kumbrink J; Schwitalla S; Greten FR; Brandl L; Klauschen F; Horst D; Kirchner T; Jung A
    J Pathol Clin Res; 2023 Jan; 9(1):73-85. PubMed ID: 36349502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A quantitative proteomics study on olfactomedin 4 in the development of gastric cancer.
    Ran X; Xu X; Yang Y; She S; Yang M; Li S; Peng H; Ding X; Hu H; Hu P; Zhang D; Ren H; Wu L; Zeng W
    Int J Oncol; 2015 Nov; 47(5):1932-44. PubMed ID: 26398045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R; Schaaf A
    Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of the olfactomedin 4 gene is associated with progression of human prostate cancer.
    Li H; Rodriguez-Canales J; Liu W; Zhu J; Hanson JC; Pack S; Zhuang Z; Emmert-Buck MR; Rodgers GP
    Am J Pathol; 2013 Oct; 183(4):1329-38. PubMed ID: 24070418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olfactomedin 4, a novel marker for the differentiation and progression of gastrointestinal cancers.
    Yu L; Wang L; Chen S
    Neoplasma; 2011; 58(1):9-13. PubMed ID: 21067260
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of MUC1 splice variants as prognostic markers in patients with ductal carcinoma in situ of the breast.
    Schmid BC; Rudas M; Fabjani G; Speiser P; Kaserer K; Leodolter S; Zeillinger R
    Oncol Rep; 2003; 10(6):1981-5. PubMed ID: 14534730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer.
    Luo Z; Zhang Q; Zhao Z; Li B; Chen J; Wang Y
    J Cancer Res Clin Oncol; 2011 Nov; 137(11):1713-20. PubMed ID: 21904905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olfactomedin 4 expression and functions in innate immunity, inflammation, and cancer.
    Liu W; Rodgers GP
    Cancer Metastasis Rev; 2016 Jun; 35(2):201-12. PubMed ID: 27178440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential Gene Expression in Ductal Carcinoma In Situ of the Breast Based on ERBB2 Status.
    Agosto-Arroyo E; Isayeva T; Wei S; Almeida JS; Harada S
    Cancer Control; 2017 Jan; 24(1):102-110. PubMed ID: 28178722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.